XML 87 R56.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Disclosures - Schedule of Significant Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Operating expenses:            
Non-cash stock compensation         $ 3,941 $ 4,632
Total operating expenses $ 27,083   $ 22,814   53,908 46,695
Loss from operations (27,083)   (22,814)   (53,908) (46,695)
Interest income 241   998   424 2,185
Change in fair value of the tranche rights 0   0   0 4,796
Other income (expense) 22   436   1,191 (1,658)
Net loss (26,820) $ (25,473) (21,380) $ (29,584) (52,293) (50,964)
Reportable Segment            
Operating expenses:            
Clinical product candidates 17,710   14,931   35,491 29,882
Pre-clinical product candidates 231   219   345 400
Non-cash stock compensation 1,899   1,882   3,941 4,632
Depreciation expense 43   34   86 57
Professional fees and other segment expenses 2,523   2,513   5,641 5,139
Total operating expenses 27,083   22,814   53,908 46,695
Loss from operations (27,083)   (22,814)   (53,908) (46,695)
Interest income 241   998   424 2,185
Change in fair value of the tranche rights         0 4,796
Other income (expense) 22   436   1,191 (1,658)
Net loss (26,820)   (21,380)   (52,293) (50,964)
Reportable Segment | Employee costs- research and development            
Operating expenses:            
Employee costs 2,594   1,887   4,761 3,881
Reportable Segment | Employee costs-general and administrative            
Operating expenses:            
Employee costs $ 2,083   $ 1,348   $ 3,643 $ 2,704